MYGN Myriad Genetics Inc
Updated
Healthcare · In Vitro & In Vivo Diagnostic Substances
Myriad Genetics Inc (MYGN) is a healthcare company in the In Vitro & In Vivo Diagnostic Substances industry, with a market capitalization of $309 million. Shares last traded at $3.23, 62.4% below their 52-week high. Over the past year the stock is down 52.6%. Net profit margin is -14.0%, below the peer median of -0.9%. Revenue declined 1.6% year over year.
Performance
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
Financials
Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q2 2026 | $-0.82 | 2026-07-31 |
| Q1 2026 | $-0.36 | 2026-05-06 |
| FY 2025 | $-3.95 | 2026-02-24 |
| Q3 2025 | $-3.88 | 2025-11-04 |
| Q2 2026 | $-3.59 | 2026-07-31 |
| Q1 2026 | $0.00 | 2026-05-06 |
In Vitro & In Vivo Diagnostic Substances peers
MYGN vs 14 industry peers (In Vitro & In Vivo Diagnostic Substances), by market cap. Updated
| IDXX | Idexx Laboratories | $41.7B | 36.58 | 9.16 | 25.0% | -1.81% |
| LNTH | Lantheus Holdings, Inc. | $6.6B | 23.94 | 4.24 | 17.7% | +0.17% |
| CLDX | Celldex Therapeutics, Inc. | $3.1B | -10.28 | 2000.34 | — | -0.32% |
| NEOG | Neogen Corp | $2.5B | -322.00 | 2.92 | -0.9% | -1.36% |
| NTLA | Intellia Therapeutics, Inc. | $1.8B | -4.44 | — | — | -0.63% |
| QDEL | Quidelortho Corp | $955M | -0.91 | 0.36 | -39.2% | -0.11% |
| ACHV | Achieve Life Sciences, Inc. | $855M | -7.49 | — | — | -2.18% |
| TKNO | Alpha Teknova, Inc. | $388M | -23.12 | 8.87 | -38.4% | -2.83% |
| MYGN | Myriad Genetics Inc | $309M | -2.74 | 0.38 | -14.0% | -0.31% |
| IMDX | Insight Molecular Diagnostics Inc. | $135M | -2.74 | 33.41 | — | +2.99% |
| ICCC | IMMUCELL CORP /DE/ | $90M | 114.19 | 2.93 | 2.6% | -0.35% |
| QCLS | Q/C TECHNOLOGIES, INC. | $15M | -0.93 | 9.79 | — | -1.57% |
| BMRA | BIOMERICA INC | $10M | -2.73 | 2.31 | -84.8% | +2.51% |
| CDIO | Cardio Diagnostics Holdings, Inc. | $5M | -0.84 | 374.80 | — | -1.08% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.